1. Introduction {#Section1}
===============

Over the past two decades, RNA-based therapeutics, such as messenger RNA (mRNA), microRNA, and small interfering RNA (siRNA), have emerged as highly attractive classes of drugs for the treatment and prevention of numerous diseases (e.g., cancers, genetic disorders, diabetes, inflammatory diseases, and neurodegenerative diseases)[@B1]-[@B6]. In comparison to the conventional small molecular drugs or proteins (specifically antibodies), RNA therapeutics can play remarkable regulatory roles in the treatment of targeted cells by either increasing the expression of a given protein or knocking out targeted genes to some varying degree. In addition to these regulatory roles, the fact that they are more convenient and easier to design than protein-based drugs, is what makes RNA therapeutics such an appealing form of treatment to researchers. However, the instability of RNAs themselves and the presence of various physiological barriers that inhibit the delivery and transfection of RNAs are what hinder their clinical application in cancer therapy [@B7], [@B8]. Moreover, the exogenous RNA is more likely to be cleared by the human body\'s intrinsic defense systems, e.g., various exonucleases and RNases responsible for RNA degradation, the major organs or tissues (e.g., kidneys and liver), and the innate immune system for RNA clearance [@B3], [@B9]. To overcome such immunogenic hurdles and make sure safe delivery of these RNA therapeutics to their target sites occurs, nanoparticle-based delivery systems have been explored as potential RNA delivery tools for *in vitro* and *in vivo* applications [@B10], [@B11].

Since the clinical success of immune checkpoint blockade (ICB)[@B12] and chimeric antigen receptor (CAR) T-cell therapies[@B13], [@B14], cancer immunotherapy treatments have drawn increasing interests. In contrast to chemotherapeutic drugs with dose-limited toxicities and potential development of drug-resistance by tumor cells, immunotherapeutics can inhibit the ability of tumor cells to evade termination by the immune system or re-program cancer-associated immune systems, and are thus more specific and able to trigger long-lasting memory anti-tumor responses. Despite these desirable features and research breakthroughs, currently used ICB antibodies and cell-based therapeutics (e.g., CAR-T) in tumor immunotherapy are far from perfect, and it is imperative to pursue new strategies for improving their safety and efficacy [@B15]-[@B17]. RNA-based therapeutics have many potential uses in immunomodulation and cancer immunotherapy, such as silencing immune checkpoint genes, activating the innate or adaptive immune system by regulating cytokines expressions, and acting as tumor antigen vaccines[@B18], [@B19]. The use of RNA-based therapeutics has recently expanded dramatically, and some have been moved to clinical trial studies during the past decade, revealing these genetic materials as excellent candidates for cancer treatment. Meanwhile, the development of various nanoparticle-based platforms, such as liposomes [@B20], polymeric nanoparticles (NPs)[@B21]-[@B26], and inorganic NPs[@B27], [@B28] for efficient delivery of RNAs provides a bright future for RNA-based therapeutics and their applications in cancer immunotherapy.

In this review article, an overview of RNA-based nanotherapeutics and recent advances, including their delivery nanoplatforms and applications in tumor immunotherapy, will be presented. Also, the various nanomaterials that have been used to deliver RNAs to tumor cells or immune cells for the induction of anti-tumor immune responses, will be highlighted. Finally, the current challenges of RNA-based nanotherapeutics will be discussed and the potential clinical value of RNA-based nanotherapeutics in tumor immunotherapy will be highlighted.

2. Nanotechnology for delivery of therapeutic RNAs {#Section2}
==================================================

2.1 RNA therapeutics {#Section2.1}
--------------------

RNA-based therapeutics have demonstrated a wide array of promising applications in the field of cancer treatment. They function as either inhibitors (e.g., siRNA and microRNA) or upregulators (e.g., mRNA) of target protein expression (Figure [1](#F1){ref-type="fig"}). siRNA is double-stranded in nature and approximately 22 nucleotides in length. Its precursor is initially recognized by Dicer RNase and is then incorporated into the RNA-induced silencing complex (RISC). The siRNA-RISC complex can bind the targeting site of mRNA, and lead to a sequence-specific cleavage by endonuclease Argonaute-2 (AGO2), thus decreasing expressions of a targeted protein [@B29]. MicroRNA is another common short regulatory noncoding RNA, used for blocking target gene expression via binding to target sites in the 3\'-untranslated regions (UTR) of protein-coding transcripts [@B30]. Firstly, primary microRNA (pri-microRNA) with a characteristic hairpin structure is recognized and processed by enzymes of Drosha and DGCR8 into ∼70 nt precursor microRNA (pre-microRNA). The resultant pre-microRNA is further cleaved by Dicer RNase, thus resulting in the formation of a mature dsRNA (microRNA). The mature microRNA is finally incorporated into RISC to induce cleavage of targeted mRNA, such as siRNAs, or translational repression, which induces a decrease of targeted proteins. Generally, the target sequences of the microRNA are frequently found in the 3\' UTR of mRNA and can often be found within non-coding or intronic regions. Therefore, each microRNA can be capable of targeting hundreds of unique mRNAs and inducing regulation of the transcriptome. However, in comparison to microRNA\'s multi-mRNA targeting abilities, siRNA has specific binding activity; therefore, each siRNA can only bind one mRNA target.

The goal of mRNA delivery is to upregulate targeted protein expressions like DNA delivery, but in contrast to DNA, mRNA therapeutics have several unique features, such as the absent risk of insertional mutagenesis, more consistent and predictable kinetics of protein expression, and relatively convenient *in vitro* synthesis[@B31]. Meanwhile, the transfection efficiency with mRNA is higher than that of DNA, especially in immune cells[@B32]-[@B34]. Each mRNA has an open reading frame (ORF) that includes two untranslated regions (UTRs) located at the 5\' and 3\' ends of mRNA, with the purpose of being recognized by the translational machinery (Ribosome). In addition to those UTRs, the mRNA\'s 5\' methyl cap and 3\' poly(adenosine) tail are also crucial for efficient translation[@B35].

2.2 Nanocarriers for RNA delivery {#Section2.2}
---------------------------------

Due to the challenges of naked RNA molecules for *in vivo* applications, i.e., extremely short half-lives (e.g., minutes), poor chemical stability, and easy degradation by nucleases[@B18], [@B36], nanotechnology provides a versatile and targeted system for the safe delivery of them [@B37]. The nanoparticle-based delivery systems not only protect RNA molecules from enzymatic degradation and immune system threats, but they also enable RNA accumulation to occur in the tumor site [@B35], [@B36]. This RNA accumulation is able to occur due to the enhanced permeability and retention effect (EPR), which is a byproduct of the diameter of the NPs, which can range from 10 to 200 nm[@B35], [@B36]. Currently, the constituents of nanocarriers applied to RNAs delivery can be classified as lipid-based nanosystems [@B38]-[@B42], polymeric nanomaterials [@B43]-[@B45], inorganic nanoparticles [@B28], [@B46], [@B47] ,or Bio-inspired nanovehicles [@B48], [@B49] (Figure [2](#F2){ref-type="fig"}). We will here summarize these nanoparticle-based platforms and further discuss their strengths and potential drawbacks for RNA delivery (Table [1](#T1){ref-type="table"}).

### 2.2.1 Lipid-based nanostructures {#Section2.2.1}

Lipid-based nanostructures are one of the most commonly used non-viral delivery systems both in academic studies and clinical trials for chemotherapeutics or genetic drugs. Several classes of lipid-based nanocarriers including liposomes, lipid nanoemulsions, and solid lipid NPs have been used for RNA delivery [@B50]. Generally, cationic lipids could be used as RNAs delivery carriers owing to their positively charged motif that has a strong interaction with negatively charged nucleic acids. As the lipids and phospholipids are the basic units of the cell membrane, lipid-based nanostructures with the similar units have a natural tendency to interact well with the cells membrane and thereby facilitating cellular uptake of RNAs. Meanwhile, the obvious other advantages of lipid-based nanostructures, such as easy preparation, good biocompatibility and biodegradability, have led them to be a promising tool in the delivery of RNA-based therapeutics. However, there are also several issues, including limited stability, easy leakage of payloads, and rapid clearance by the kidneys or liver should be addressed before these lipid-based delivery systems are put to perform at clinical or *in vivo* levels.

### 2.2.2 Polymer-based nanomaterials {#Section2.2.2}

Polymer-based nanomaterials are well-studied systems for RNA delivery [@B51], which are classified into two major categories: natural or naturally derived polymers, and synthetic polymeric conjugates [@B43], [@B44]. Natural or naturally derived polymers such as chitosan, which is composed of N-acetyl-d-glucosamine and d-glucosamine, poly-l-lysine, which consists of repeating units of lysine, and atelocollagen, occur in nature and are produced by all living organisms. The advantages of these nanoparticles are good biocompatibility and biodegradability, and low cost of production [@B52]-[@B54]. Among the synthetic polymers, poly(dl-lactide-co-glycolide) (PLGA), polyethyleneimine (PEI), polyvinyl alcohol (PVA), polyethylene glycol (PEG), poly-l-lactic acid (PLA), etc., are the most common polymers used in delivery of RNAs due to their high stability, good biocompatibility and biodegradability [@B55]-[@B59]. Meanwhile, it is important to note that these synthetic polymers are easy to functionalize with ligand bindings for targeting, and with responsive units that respond to chemical, biological, and physical stimuli for the controllable release of cargoes. However, some synthetic polymers (e.g., PLGA) could not be directly applied in RNA delivery due to no cationic units on them, thus leading to low electrostatic interaction between polymers and RNAs. One method to overcome this problem is modification with various cationic motifs (e.g., PEI) or co-assembly with cationic polymers into nanostructures, it is also noted that the most cationic units or polymers are nondegradable, which may be associated with potential toxicity issues [@B22].

### 2.2.3 Inorganic nanoparticles {#Section2.2.3}

Recently, various inorganic NPs, such as mesoporous silica nanomaterials (MSNs) [@B60]-[@B62], carbon nanotubes (CNTs) [@B63], quantum dots (QDs) [@B64], and metal nanostructures[@B65] (e.g., iron oxide and gold NPs), are reported as carriers for delivery of RNAs. These inorganic NPs are synthesized by biodegradable polymers and inorganic particles. Consequently, the properties of these nanoparticles are easy to control, and their advantages include surface modification, good reproducibility, and easy cell uptake. However, the level of degradability of all of the inorganic materials has yet to be determined, and potential toxicity could be a problem [@B58]. As a result, more extensive *in vivo* studies are still needed.

### 2.2.4 Bio-inspired nanovehicles {#Section2.2.4}

In recent studies, some bio-inspired nanovehicles, such as DNA-based nanostructures [@B66], [@B67], exosome-mimetic nanovesicles [@B68], [@B69], and red cell member-based ghosts [@B70] have been explored as gene and drug carriers to enhance delivery to targeted cells. The exosome is a bilayer membrane-coated vesicle secreted by cells, whose function is triggering intercellular communication by transferring payload mRNA, miRNA, or proteins from one cell to another. Studies have shown that these exosome nanovesicles exhibit good biodegradability, which can be attributed to their morphology and surface properties which are similar to those of natural cells. Originated from cell membrane proteins, cell membrane-based ghosts are another cell-derived nanovesicles, which possess identical physiochemical properties, such as topological/physiological activities. These cell membrane-based ghosts have a promising future in nanotechnology for a variety of biomedical applications, such as targeted delivery of RNA therapeutics, and tissue regeneration [@B71]. In comparison to other drug delivery systems, the advantages of these bio-inspired nanovehicles are low toxicity, strong targeting abilities, and low immune response induction. However, the high cost of production and vesicle stability should be considered in further clinical applications.

3. RNA nanotherapeutics for tumor immunotherapy {#Section3}
===============================================

Tumor immunotherapy can induce a synergistic killing effect on tumor cells through primarily targeting the immune system rather than the tumor cells themselves. Current immunotherapeutics, including antibodies, proteins, and engineered immune cells (e.g., CAR-T) are promising strategies for cancer treatment and some of them have been successful in clinical applications. However, these therapies still face some critical issues, such as insufficient efficacy (e.g., ICB has shown activity in approximately 15%-25% of patients [@B72]), high costs and side-effect [@B15], [@B17]. RNA-based agents provide some advantages in immunomodulation, such as high selectivity for silence or increased expression of specific targets and low risk of off-target hitting. Using RNA therapeutics in conjunction with nanomaterials is a valuable strategy to improve the efficacy of immunomodulation for cancer treatments. When used as partners in synergistic combinations, more efficient and personalized results will be reached, enabling the combination to compete with current immunotherapies already on the market.

3.1 Nanostructure-mediated siRNA delivery for immunotherapy {#Section3.1}
-----------------------------------------------------------

Recently, many approaches have demonstrated that silencing the crucial factors of tumor progression in cancer cells or knocking out/down the immunosuppressive genes in cancer [@B73] and cancer-associated immune cells can effectively induce an anti-tumor immune response [@B74], [@B75]. Nanomaterials can act as Trojan horses by delivering siRNAs, for regulating the immune response, to cancer or immune cells [@B76], [@B77]. Here, we summarize the potential siRNA targets in tumor or immune cells, as well as nanostructure delivery systems for siRNA-mediated immunotherapy (Table [2](#T2){ref-type="table"}).

3.1.1 Tumor cells-targeted siRNA immunenanotherapy {#Section3.1.1}
--------------------------------------------------

Tumor cells can develop numerous strategies to promote immune system escape and drive the generation of an immunosuppressive microenvironment. For example, tumor cells can effectively induce and recruit distinct immunosuppressive cells, by promoting the secretion of some pro-tumor cytokines and chemokines[@B107], such as interleukin-6 (IL-6), IL-10, transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and C-X-C motif chemokine 5 (CXCL5). Meanwhile, the tumor-infiltrating suppressive cells evade immune surveillance by secreting or expressing a few immunosuppressive molecules that disrupt antigen presentation of dendritic cells (DCs) and suppress proliferation and activation of T cells [@B108], [@B109]. Additionally, tumor cells could evade immunological eradication by downregulating antigen expression, and upregulating the expression of immune checkpoint proteins (e.g., PD-L1) or "don\'t eat me" signals (e.g., CD47) [@B110], [@B111]. CD47 is over-expressed on the cancer cell surface, which enables escape from immune system recognition by labeling the cells with the "self" marker.

In the last few years, tumor cell-targeted siRNA nanotherapeutics have been centered on the downregulation of immune checkpoint proteins, "don\'t eat me" signals, anti-inflammatory cytokines, etc., for inducing anti-tumor immune-responses has been gaining increasing attention (Figure [3](#F3){ref-type="fig"}). For example, Yang et al. developed a systemic delivery strategy based on HA-coated Lipid NPs for delivery of CD47 siRNA to melanoma cancer cells, which induced an efficient knockdown of CD47 in cancer cells [@B85]. CD47 silence effectively suppressed the tumor growth in a melanoma mice model. Similarly, using siRNA-based nanotherapy for the direct knockdown of immune checkpoints or anti-inflammatory cytokines on tumor cells has also enhanced anti-tumor immune responses and showed significant inhibition of tumor growth *in vivo*. For instance, Xu et al. developed a mannose-modified liposome-protamine-hyaluronic acid NPs (LPH) for encapsulating with TGF-β siRNA to B16F10 melanoma tumor cells [@B83]. Meanwhile, the authors developed another lipid-calcium-phosphate NP (LCP) to deliver tumor antigens (i.e., Trp 2 peptide and CpG oligonucleotide) to the dendritic cells, with the purpose of eliciting a systemic immune response. The *in vivo* results displayed that silencing of TGF-β by LPH boosted the vaccination efficacy of LCP, and significantly inhibited tumor growth.

The exciting anti-tumor effect produced by the combination of two NPs suggested the combo therapy by two or more therapeutics will induce a more powerful anti-tumor immune response and offer a powerful platform for cancer treatment. Based on this, some strategies that combine RNA-based nanotherapeutics with photodynamic or chemical agents are being reported in recent studies [@B80], [@B81]. For instance, Dai et al. reported a pH-responsive nanosystem that when co-loaded with PD-L1 siRNA and a mitochondrion-targeting photosensitizer and given to tumor cells, induced the synergistic anti-tumor effect by combing photodynamic and immunotherapy [@B80]. The *in vitro* and *in vivo* results reveal that the nanosystem not only efficiently induced an immune response by photodynamic therapy, but also subsequently induced a siRNA-mediated immune checkpoint blockade that further activated systemic anti-tumor immune responses, and thereby led to significant growth inhibition for melanoma. A similar result has also been reported by Qiao et al. They designed a ROS-responsive nanotheranostic system which combined temozolomide (TMZ)-mediated chemotherapy and immunomodulation by siTGF-β-based therapy on glioblastoma [@B84]. In this study, cationic poly\[(2-acryloyl)ethyl(p-boronic acid benzyl)diethyl ammonium bromide\] (BA-PDEAEA, BAP) was used to condense with TGF-β siRNA, the zwitterionic lipid-based envelopes (ZLEs) were then coated on polymer-siRNA nanocomplex, and TMZ was loaded into the core of the nanotheranostic NPs (LiB(T+AN\@siTGF-β), LBTA). The NPs were finally modified with an angiopep-2 peptide that enabled the NPs to cross the blood-brain barrier (BBB) and accumulate into the glioblastoma tumor region. Both *in vitro* and *in vivo* results demonstrated that this nanotheranostic NPs effectively down-regulated TGF-β expression of tumor cells and dramatically enhanced the efficacy of TMZ mediated chemotherapy. Meanwhile, it showed that the survival time of glioblastoma tumor-bearing mice was significantly prolonged after the synergistic combination treatment.

In addition to directly silencing the immunosuppressive genes, combination therapy with knock out/down oncogenic genes, through siRNA and immune checkpoint blockade therapy, may provide another promising method for cancer treatment. For example, Matsuda et al. used the extracellular vesicles (EVs) to develop a biological nanoparticle-mediated delivery system for intrahepatic delivery of β-catenin siRNA to hepatocellular carcinoma (HCC)[@B88]. In this study, the β-catenin siRNA EVs and anti-PD-1-based therapy were systemically administrated together. The *in vivo* results demonstrated the therapeutic EVs improved CD8^+^ T cells infiltration and priming, and thus enhanced the anti-tumor effect of anti-PD-1.

### 3.1.2 Immune cells-targeted siRNA immune-nanotherapy {#Section3.1.2}

During tumor progression, the immune cells can also recognize and eliminate tumor cells, which are known as tumor immunosurveillance. However, tumor cells can also change the host\'s immune system and escape immune system control by re-education or re-programing the immune cells, e.g., recruitment of various immunosuppressive cells to the primary microenvironment of the tumor, induction of immune cells into pro-tumorigenic types and inhibition of the anti-tumor activity of immune cells [@B109]-[@B111]. Therefore, suppressing the immunosuppressive cells or modulating immune cells to anti-tumorigenic types would be an attractive approach to inhibit tumor immune escape and slow tumor growth (Figure [4](#F4){ref-type="fig"}).

#### 3.1.2.1 T cells {#Section3.1.2.1}

Like cancer cells\' highly/over-expressed inhibitory molecules (e.g., PD-L1), some activated T cells also over-express corresponding inhibitory molecules [@B112], [@B113], such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and mucin-containing protein 3 (TIM-3). All these inhibitory signals are known as immune checkpoints, which can downregulate, T cell activities and therefore prevent the elimination of tumor cells by effector T cells [@B113]. Thus, targeting the immune checkpoints of T cells may also boost the anti-tumor effects. Given this, Li et al. constructed cationic lipid-assisted PEG-PLA-based NPs for efficiently delivering CTLA-4 siRNA to T cells [@B90]. The NPs consisted of poly(ethylene glycol)-block-poly(d,l-lactide) (PEG5k-PLA11k) and the cationic lipid N,N-bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryoxycarbonyl-aminoethyl) ammonium bromide (BHEM-Chol) polymers which could encapsulate with CTLA-4 siRNA by electrostatic interaction. Although the NPs were only internalized by 4-6% of T cells *in vivo*, it promoted an \~ 2-fold increase in effector CD8^+^ T cells (approximately 40.3% vs. 18.9% of PBS), and the ratio of CD4^+^ FOXP3^+^ Tregs was decreased by \~ 2.5 fold compared to PBS. Accordingly, these NPs could effectively inhibit tumor growth and prolong survival time in mice with melanoma.

#### 3.1.2.2 TAMs {#Section3.1.2.2}

Macrophages are professional phagocytes for eliminating pathogens and cellular debris. In the tumor microenvironment, tumor-associated macrophages (TAMs) usually are either pro-tumor M2 type or anti-tumor M1 type. The macrophages or monocytes are usually recruited to the tumor region and polarized to M1-type at the initial stages of tumor formation, and in advanced tumor progression stage, the macrophages will convert from M1 to M2 type, which thus exerts pro-tumor effects by helping block CD8 T cells [@B114], [@B115]. Conclusively, reducing the survival and recruitment of TAMs in tumor site or performing targeted delivery of therapeutics to the M2-like TAMs, for depleting them from tumors or converting them to M1 type, would be promising strategies for cancer immunotherapy [@B116].

Recent studies indicated that the CCL2-CCR2 [@B117] and CCL3-CCR1/CCR5 signaling [@B118] were required for the recruitment, retention, and the phenotypic recruitment of TAMs. They also indicated that the cytokines [@B119], including colony stimulating factor 1 (CSF1) and vascular endothelial growth factor (VEGF), are known to recruit monocytes as well. Given this, Qian et al. reported a molecularly-targeted strategy based on dual-targeting nanoparticles (M2NPs) that deliver colony stimulating factor-1 receptor (CSF-1R) siRNA to M2-like TAMs for the specific blockade of the survival of M2-like TAMs, which results in the depletion of them from melanoma tumors [@B93]. The siRNA-carrying M2NPs can inhibit the production of immunosuppressive factors (e.g., IL-10 and TGF-β), but also increase the expression of immunostimulatory cytokines (IFN-γ and IL-12) and CD8^+^ T cells infiltration (2.9-fold). Moreover, it effectively induced the anti-tumor activity of T cells by down-regulating expressions of the exhaustion markers (PD-1 and Tim-3) and stimulating secretion of IFN-γ (6.2-fold). *In vivo* results confirmed that M2NPs led to a dramatic elimination of M2-like TAMs (52%), inhibition of tumor growth (87%), and prolonged survival.

Conde et al. presented peptide-functionalized gold nanoparticles (AuNPs) for delivery of VEGF siRNA to M2-like TAMs where a decrease in the accumulation in lung tumor tissue was observed, alongside enhanced tumor growth inhibition in a lung cancer orthotopic murine model [@B92]. VEGF is a key angiogenic factor, which is highly expressed on M2-like TAMs and well known to promote cancer progression and metastasis. In this study, the authors proved that siRNA mediated gene silencing for inhibiting TAMs accumulation could be achieved by targeting the VEGF pathway, which also indicated that modulation for TAMs would induce an anti-tumor immune response and could be a potential target for cancer treatment.

#### 3.1.2.3 DCs {#Section3.1.2.3}

DCs are the most important antigen-presenting cells (APCs), which could capture, process, and present tumor antigens to either naive CD8^+^ or CD4^+^ T cells. The functions of DCs are either mediating immune tolerance or inducing an anti-tumor immune response. Generally, DCs express a variety of co-inhibitory molecules [@B120], such as suppressors of cytokine signaling (SOCS) 1, signal transducers and activators of transcription-3 (STAT3), and indoleamine 2,3-dioxygenase (IDO). All of these molecules may suppress the antigen presentation process of DCs. Studies have shown that knockdown of these molecules by RNAi would be an effective strategy for DCs-based immunotherapy [@B121]-[@B124]. Based on this, Heo et al. reported a PLGA polymeric NPs that combined the delivery of tumor antigens and SOCS1 siRNA to DCs that induced an enhanced anti-tumor immune response [@B102]. SOCS1 functions as a broadly immuno-suppressive protein which can directly inhibit antigen presentation of DCs to T cells, and it also acts as a negative regulator of Janus kinases (JAKs), which induce immune tolerance. In this study, PLGA polymeric NPs with the loading of SOCS1 siRNA and OVA peptide were efficiently taken up by bone-marrow-derived dendritic cells (BMDCs) and this showed proof of the significant knockdown effect on the expression of SOCS1. The downregulation of SOCS1 in BMDC further led to a drastic enhancement in cytokine production, and finally resulted in the essential induction of anti-tumor immune response.

#### 3.1.2.4 Others {#Section3.1.2.4}

Neutrophils has been described as part of the innate immune response, but recent studies have shown that neutrophils can be a key negative regulator for adaptive immune responses by suppressing T cell proliferation, and therefore they also be so-called myeloid-derived suppressor cells (MDSCs)[@B125]. MDSCs have been identified to facilitate the development of an immunosuppressive tumor microenvironment [@B126]. Many studies have also demonstrated MDSCs are critically involved in immunosuppressive effects through the high expression of metabolic enzymes [@B127], [@B128], such as IDO, and arginase-1 (ARG1), cytokines[@B129], [@B130], and chemokines, such as TGF-β and IL-10. Meanwhile, the recruitment of MDSCs relies on the chemokines [@B131] (e.g., CCL2). Due to the important role in tumor-associated immune suppression of MDSC, many studies were focused on exploring therapeutic strategies to eliminate these cells or to modulate their functions [@B132]-[@B135]. For example, Leuschner et al. introduced monocyte-targeting lipid NPs for the delivery of CCR2 siRNA to the inflammatory monocyte [@B104]. The results showed efficient inhibition of CCR2 expression by siRNA-mediated CCR2 gene silencing in monocytes that prohibited their accumulation in inflammatory sites and reduced the number of TAMs.

3.2 Nanostructure-mediated microRNA delivery for immunotherapy {#Section3.2}
--------------------------------------------------------------

Non-coding RNAs are usually classified into small non-coding RNA (e.g., microRNA) and long non-coding RNA (lncRNA, \> 200 nt), depending on their size. Recent studies of lncRNAs have indicated that lncRNAs function as crucial regulators in various immunity processes, including immune cells differentiation and function, regulation for tumor microenvironment, but the detail regulatory mechanisms remain unclear [@B136]. While current studies are mainly focused on the development of the lncRNAs for immune regulation and the functional relationship between lncRNAs and immunity, and there were limited reports on lncRNAs-based nanomaterials for immunotherapy, we might believe that lncRNAs could become a novel therapeutic agent in cancer immunotherapy.

In addition, recently studies have shown that microRNAs are associated with the modulation of various pathways of cancer and immune cells. MicroRNAs usually produce competition for oncogenic and tumor suppressive effects by blocking either tumor suppressive mRNA or oncogenic mRNA [@B137]-[@B139]. Generally, oncogenic microRNAs are highly/over-expressed in cancer cells, while tumor-suppressive microRNAs are under-expressed. Restoration of tumor-suppressive microRNAs could both inhibit cancer cell proliferation and induce cell apoptosis. Because of these possibilities, this technique has been viewed as novel therapeutics for cancer treatment [@B6], [@B140]. Ultimately, it is necessary to carefully assess the specific roles of microRNAs in cancer or immune cells, and develop an effective and safe microRNA-based therapeutic for cancer treatment.

### 3.2.1 Tumor cells-targeted microRNA immunonanotherapy {#Section3.2.1}

As mentioned above, tumor cells will up-regulate the expression of immune checkpoint proteins, or "don\'t eat me" signals, to construct an immunosuppressive microenvironment. microRNA acts as a gene regulator, which can either be used to directly inhibit expressions of immune escape factors and pro-inflammatory cytokines or act as oncogenic factors for facilitating immune system evasion by tumor cells[@B141]. For example, many microRNAs including miR-34a, miR-200, miR-142-5p and miR-424, et al. have been found to be involved in PD-L1 expression levels in several cancer cells [@B142], [@B143]. Among them, miR-424 not only activates T cells immune response through direct targeting of PD-L1, but also can restore the chemosensitivity of ovarian cancer cells [@B144]. However, some microRNAs, such as miR-20b, miR21, and miR-130b, have been found to inhibit PTEN expression in colorectal cancer, but they in turn promote PD-L1 upregulation [@B145]. MicroRNA antagonists are short, single-stranded oligonucleotide molecules complementary to microRNA sequences that have recently been used for targeting and reducing microRNA activity. Therefore, using antagonists of microRNA will also decrease oncogenic microRNA activity and provide promising results of targeted genes for immunomodulation. To date, there has been a limited report by using nanotechnology for the delivery of microRNA to tumor cells for triggering an anti-tumor immune response, but there is high confidence that it would be a potential strategy for cancer immunotherapy.

### 3.2.2 Immune cells-targeted microRNA immunonanotherapy {#Section3.2.2}

Many studies have shown that microRNAs are important in the modulation of innate and adaptive immune-responses via controlling the differentiation and activation of immune cells and the maintenance of immune proinflammation factors [@B141]. These microRNAs either contribute to or repress the immune cells to initiate anti-tumor responses (Figure [5](#F5){ref-type="fig"}). Specifically, the upregulation of miR-146a [@B146] and miR-21[@B147] attenuate M1-like TAMs activation by targeting TLR/NF-κB pathway, but miR-155[@B148], [@B149] promote M1-like TAMs polarization by targeting SOCS1 or targeting the negative regulator of NF-κB and TNF-α-induced protein 3. Along with TAMs, some microRNAs, such as miR-150 and miR-181a/b, have been found to control the differentiation of NK cells [@B150]. The use of miR-148 and miR-22 inhibitors may also promote DCs maturation [@B151]-[@B153]. In addition, the differentiation and functions of different T cell subsets are regulated by microRNAs [@B154], [@B155]. For example, miR-155 are more in favor of Th1 phenotype [@B156], miR-326 promote Th17 differentiation [@B157], and miR-10a and miR-17/92 cluster regulate T follicular helper maturation [@B158].

Given the potential applications of microRNA-based therapeutics in cancer immunotherapy, a variety of microRNA-based nanomaterials that can efficiently target immune cells for immunomodulation have been developed (Table [3](#T3){ref-type="table"}). For instance, Zhang et al. designed lipid-coated calcium phosphonate nanoparticles (CaP/miR\@MNPs) which were further conjugated with mannose for specific delivery of miR155 to TAMs [@B159]. The results demonstrated that CaP/miR\@MNPs could successfully transfer pro-tumor M2-like TAMs to antitumor M1-like TAMs, and therefore elicit a potent antitumor immune response, whilst inhibiting tumor growth. Similarly, Parayath et al. developed a CD44 targeting hyaluronic acid-poly(ethylenimine) (HA-PEI)-based nanoparticle for the delivery of miR-125b to peritoneal macrophages [@B160]. Overexpression of miR-125b in macrophages would promote M1-like TAMs activation and lead to inhibition of primary tumor growth and metastasis. *In vivo* results showed that there was a more than 6-fold increase in the ratio of M1 to M2 TAMs and 300-fold increase in the ratio of iNOS (M1 marker) to Arg-1 (M2 marker) in TAMs after treatment with HA-PEI-125b nanoparticles. All of the examples above indicated that successfully inducing M1-like TAMs polarization would enhance anti-cancer immunotherapy.

3.3 Nanostructure-mediated mRNA delivery for immunotherapy {#Section3.3}
----------------------------------------------------------

mRNA emerging as a cancer therapeutic has drawn increasing attention due to its multiple unique features[@B166], such as the absent risk of insertional mutagenesis, more consistent and predictable kinetics of protein expression, and relatively convenient *in vitro* synthesis. However, its poor stability (easily degraded by the nucleases) and propensity for immunostimulation have greatly hindered the *in vivo* application. Moreover, it very difficult for the larger mRNA molecules with negative charges to enter antigen-presenting cells (APCs) directly. Nanoparticle-based platforms with high cytosolic transportation and reduced renal filtration, could be emerging as a promising mRNA delivery tool to protect nucleic acids from enzymatic degradation and withstand multiple intracellular and extracellular barriers [@B35], [@B167]. Here, we will describe two examples to present the advances of mRNA nanomedicines in immunotherapy applications, including vaccination and cell engineering.

### 3.3.1 mRNA-based NPs for vaccination {#Section3.3.1}

mRNA-based vaccines show a promising alternative due to the high potency, safe administration, and capacity for rapid development and low-cost manufacture[@B168], [@B169]. Recent nanotechnological advances have largely overcome the issues of *in vivo* mRNA delivery, and therefore mRNA-based nanovaccines have recently attracted increasing attention because of the promising results achieved in many anti-tumor vaccination studies in animal models [@B170], [@B171]. Meanwhile, the mRNA-based vaccine could effectively carry out antigen-encoding mRNA to antigen presenting cells (APCs) *in vivo* directly. Also, the mRNA-based vaccine is unlimited in molecular structures and number of tumor antigen proteins. When the nanocarriers efficiently deliver these antigen-encoding mRNAs into APCs, the mRNAs will be released and translated into tumor antigenic proteins in the cytoplasm of APCs, which are then processed into peptide epitopes for subsequent binding with the major histocompatibility complex (MHC) class I *via* cross-presentation pathway. The MHC-peptides are finally transferred to the cell surface of APCs for activation of CD8^+^ T cells, leading to corresponding anti-tumor immune responses (Figure [6](#F6){ref-type="fig"}). Efficient *in vivo* mRNA delivery and induction of strong cytotoxic T cell response are the key prerequisites for cancer immunotherapy by mRNA-based nanovaccines. There are so many advantages and disadvantages for *in vivo* application of mRNA-based nanovaccines, and many review articles have summarized the advertences of mRNA-based nanovaccines in cancer therapy. Here we just describe one example to present the mechanism of anti-tumor response by nanovaccine.

A lipid nanovaccine with the loading of tumor-associated antigens mRNA (e.g., gp100 and TRP2) was designed by Oberli et al. [@B172]. In this study, the lipid nanoparticle that consisted of an ionizable lipid, a lipid-PEG, a phospholipid, cholesterol, and an additive was developed. The ionizable lipid was used for complexation with the negatively charged mRNA and also helped with cellular uptake. The results showed the NPs worked well for the delivery of mRNA to dendritic cells, macrophages, and neutrophils, and effectively led to strong activation of CD8^+^ T cells after a single immunization in the B16F10 melanoma model. Moreover, after treatment with these NPs, B16F10 melanoma tumor experienced shrinkage, and mice survival was significantly extended. The exciting result from this study demonstrated that the induction of cytotoxic T cell response by mRNA nanovaccine would be an excellent candidate in the application of cancer treatment.

In the nanovaccine field, the nanostructures with CpG oligodeoxynucleotides that act as immuno-adjuvants for inducing immunostimulatory responses are very attractive. CpG oligodeoxynucleotides are Toll-like Receptor 9 (TLR9) agonists, which are expressed in human B and plasmacytoid dendritic cells. Recent studies demonstrated CpG not only could induce apoptosis of tumor cells with high-expression of the TLR9 receptor, but also enhance NK cell activation and promote activation of anti-tumor immune response by combining with various of cytokine treatments [@B173], [@B174]. Therefore, CpG-based nanotherapeutics can only benefit from combination with strategies of immune checkpoint blockade.

3.3.2 mRNA-based NPs for T cell engineering {#Section3.3.2}
-------------------------------------------

As a novel immunotherapy method, CAR-T therapy has achieved great success in treating patients with hematological malignancies [@B13], such as leukemia and lymphoma therapy. Currently, the most common techniques for the development of CAR-engineered T cells are using viral gene transduction by virus-mediated delivery. However, using viral vectors may lead to the potential insertional mutagenesis and genotoxicity for effector T cells[@B15]. Meanwhile, the feared side-effects would happen when virus vectors transduced cells [@B175]. Hence, more precise T cell manipulations are currently under investigation.

Using mRNA instead of DNA as T cell engineering therapeutics (Figure [7](#F7){ref-type="fig"}) is attractive due to the multiple unique features of mRNA [@B176], [@B177]. Meanwhile, the use of nanocarriers protect mRNA therapeutics from degradation and may help with cellular uptake and endosomal escape. In addition, nanocarriers provide further advantages for the engineering of immune cells, e.g., coating with specific ligands for increasing cell binding and cellular uptake, and carrying multiple RNA payloads. Moffett et al. developed a targeted nanocarrier for reprogramming T cells by delivery of several mRNAs to T cells [@B178]. The nanocarrier consisted of negatively charged polyglutamic acid (PGA), poly(β-amino ester) (PBAE) polymers and T cell targeting ligands (e.g., anti-CD3 and anti-CD8). In this study, the authors first used their nanocarrier to deliver FoxO1 (Forkhead box O1, a transcription factor to promote the generation and maintenance of memory T cells) mRNA to CAR T cells for overexpressing FoxO1. FoxO1 overexpression can bias CAR-T-cells toward a central memory phenotype and therefore improve the anti-tumor activity of CAR T cells. In addition, the authors developed mRNA nanocarriers to transiently express genome-editing proteins (CRISPR) for efficiently knocking out T cells receptors in CAR-programmed lymphocytes. The results demonstrated that the NPs could effectively transport mRNAs to targeted T cells, and subsequently led to the targeted T cells to express selected proteins. Next, we will describe CRISPR-Cas9 nanotechnology mediated cell engineering and its application in immunotherapy.

3.4 CRISPR-Cas9 nanotechnology for cell engineering {#Section3.4}
---------------------------------------------------

CRISPR/Cas9 system (clustered regularly interspaced short palindromic repeats) [@B178], is an RNA-guided DNA targeting technology, which has been widely applied to genome editing [@B180], [@B181], gene therapy [@B182] and manipulation of induced pluripotent stem cells (iPS) studies[@B183]. The CRISPR-Cas9 gene editing machinery is comprised of two essential components, i.e., sgRNA and DNA endonuclease Cas9 (Figure [8](#F8){ref-type="fig"}A). The Cas9 protein functions in locating and cleaving targeted DNA, and the guide RNA has a 5′ end that is complementary to the target DNA sequence. Only when two macromolecules are forming a complex, will the cleavage activity of Cas 9 begin to be triggered (Figure [8](#F8){ref-type="fig"}A). In cancer immunotherapy, CRISPR-Cas9-mediated genome editing is usually applied to knockout the genes that encode inhibitory receptor proteins of tumor or T cells, such as PD-1, PD-L1, and CTLA-4[@B184]-[@B186]. In 2016, a case of CRISPR-Cas9 application in a clinical trial of T cells engineering by deleting PD-1 was performed in China, and the result was promising[@B187], indicating the potential value of CRISPR-Cas9-mediated genome editing in immunotherapy.

While CRISPR-Cas9 has been used as a particularly versatile and operationally simple tool for gene editing in many cell types, the effective delivery of CRISPR-Cas9 system into targeted T cells is still the common issue for efficient genome editing. In addition, off-target effects are also found in many CRISPR-Cas9-mediated gene-editing studies [@B188]. To reduce these effects, various nanocarriers have been developed as the delivery of CRISPR-Cas9 system[@B189]-[@B191], which may be applied to manipulations of immune cells (TAMs, B cells, and T cells) and tumor cells (Figure [8](#F8){ref-type="fig"}B). In addition, compared to the viral vectors with high immunogenicity, various types of lipid-based or polymer-based nanocarriers, which are actively targetable with low immunogenicity, showed exciting delivery efficiency[@B192], [@B193]. For example, Ray et al reported a nanomaterial platform based cationic arginine-coated gold nanoparticles[@B194], which delivered CRISPR-Cas9 gene editing machinery into macrophage cells for knockout expression of "don\'t eat me" signals (SIRP-α). The NPs based nanoplatform has shown ∼90% delivery efficiency as well as ∼30% gene editing efficiency. The *in vitro* experimental results also showed a 4-fold increase in the innate phagocytic capabilities of the macrophages by using this strategy to turn off the "don\'t eat me" signal on macrophages, indicating this strategy may be a promising tool for the development of "weaponized" TAMs for cancer immunotherapy. Similarly, Cheng et al. proposed a double emulsion method by complexing plasmids with stearyl polyethyleneimine (stPEI) as the core to form human serum albumin (HSA) (plasmid/stPEI/HSA) NPs for delivery of CRISPR/Cas9 [@B195]. The NPs could disrupt or silence the expression of PD-L1 by CRISPR/Cas9-mediated gene editing.

4. Conclusions and future perspectives {#Section4}
======================================

During the past few years, immunotherapy has shown to be one of the most promising therapeutic strategies and has resulted in a paradigm shift in the treatment of cancers [@B13], [@B112]. RNA-based therapeutics provide several advantages in immunomodulation and cancer vaccines, which will serve as a competitor and as a current immunotherapies partnership to achieve synergistic combinations for more efficient and personalized results [@B75], [@B169], [@B176], [@B196]. Compared to the conventional proteins, antibodies, and cell-based therapeutics (e.g., CAR-T), RNA-based therapeutics including siRNA, microRNA, and mRNA can either knock out or knock down targeted genes or upregulate expressions of specific proteins, and such features of RNA-based therapeutics cause high selectivity and low risk of off-target hitting. Meanwhile, RNA-based therapeutics have become much more diverse and broad in regulatory functions in immunotherapy than the other antibody or protein-based therapies. For example, RNA-based therapeutics could activate rapid and effective anti-cancer immune response by inducing immunogenic cell death of tumor cells, and thus may skip the requirement of deep tumor penetration-a significant hurdle faced by traditional cancer nanomedicines. Moreover, the development and production of RNA therapeutics are very convenient, rapid and cost-effective [@B197]. The success of pre-clinical studies has led to the initiation of clinical trials of different forms of RNA therapeutics for cancer immunotherapy (Table [4](#T4){ref-type="table"}).

Given the potentials of these RNA therapeutics, various nanoparticle-based delivery systems, such as lipid-based, polymeric, inorganic and bio-inspired nanomaterials have been explored extensively [@B49], [@B167], [@B198], [@B199]. These nanoparticle-based delivery systems not only carry a high dose of therapeutic payloads to targeted cells or tissues, but also show the same regulatory functions in immunotherapy with RNA therapeutics. In addition, the combination of RNA-mediated nano-immunotherapy with chem- or photodynamic therapies demonstrated promising results in an animal model[@B81], [@B106]. Meanwhile, combining RNA-mediated nanotherapy with current immunotherapies (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1) is also a great opportunity to enhance cancer treatments [@B133]. However, there are still several issues need to be solved before such applications are translated to the clinic.

To begin with, some of the main barriers that hinder the stability and *in vivo* safety of the various nanomaterial carriers include cytotoxicity and undesirable immune stimulation [@B21], [@B200]. As mentioned previously, potential *in vivo* toxicity issues can arise from the use of cationic units in polymeric NPs, payload leakages from lipid-based nanostructures, and the non-biodegradability of inorganic NPs [@B20], [@B38]. In addition, the NPs may be recognized as a foreign substance, and thus easily excreted by renal/hepatic clearance or eliminated by the innate immune systems [@B198]. To address these issues, nanocarriers should be bio-compatible and capable of biodegradability by modulating the surface of the NPs with biomolecules or proper hydrophilic materials such as PEG.

Secondly, nanocarriers must increase cell targeting and cell internalization. For example, for targeting tumor cells to silence PD-L1 by RNA-based NPs, it needs to target as many of them as possible, thus requiring high accumulation and deep tumor penetration. To increase cellular uptake and thus increase the effectiveness of RNA delivery, NPs could be coated with targeting ligands, which would increase the chance of binding to the targeted cells. In addition, effective on-demand RNA delivery and release would become feasible through the incorporation of backbones of that are sensitive to different stimuli, either endogenous (e.g., pH, enzyme, and redox) or exogenous (e.g., temperature, electricity, light, magnetic force, ultrasound)[@B201], [@B202]. Such a feature of nanocarriers would enable optimal spatial and temporal release of RNA payloads. Despite many nanovesicles infiltrating the targeted cells through the endocytic pathway, they must still overcome the barriers that endosomes and lysosomes pose before achieving the ultimate goal of cytosolic release of RNA therapeutics [@B203]. Generally, nanomaterials are transported into the endosome, which then fuses with lysosomes and ultimately destroys the RNA cargoes. Some specific targeting peptides (e.g., HA) or surfactants can be used in the preparation of nanocarriers to enable the endosomal/lysosomal escape via the proton sponge effect or membrane lysis. It should be noted that many stimuli-responsive nanomaterials had potential dose-dependent cytotoxicity. This cytotoxicity was due to the stimuli-responsive motif often being limited by insufficient biocompatibility or the need for bio-degradability [@B204]. Meanwhile, the complexity of the architectural design and difficulties in the synthesis of these NPs are likely to hamper their clinical translation. Therefore, the benefit-to-risk ratio for the development of responsive NPs needs to be balanced, and the issues related to the responsive characteristics would eventually need to be solved.

In summary, the goal of the current review article was to summarize and highlight the RNA-based nanotherapeutics for the immunomodulation and enhancement of cancer immunotherapy. Given the convenience and importance of RNA therapeutics in cancer immunotherapy, using nanomaterials for effectively delivery of RNA to a targeted tumor or immune cells for triggering anti-tumor immune response have already produced some exciting results in the treatment of cancer. Meanwhile, by combining RNA-mediated immunomodulation with ICB immunotherapy, chemotherapy, and photodynamic therapy, synthesized effects have been noted and a bright future for the clinical use of cancer treatment awaits. Although the RNA delivery nanoplatforms for clinical applications is still challenging, some issues need to be solved before this nanotherapeutics translated from the bench to the bedside. We believe that the RNA-mediated nano-immunotherapy has great potential to overcome some of these shortcomings and has the opportunity to be used for cancer treatment in the future.
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![The biological mechanism of siRNA, microRNA, and mRNA for inhibition of target protein expressions or up-regulation of a given protein.](thnov10p0281g001){#F1}

![Schematic representation of the 4 nanoparticle-based platforms used in the RNA delivery.](thnov10p0281g002){#F2}

![Potential strategies of tumor cells-targeted siRNA nanotherapeutics for cancer immunotherapy.](thnov10p0281g003){#F3}

![Potential siRNA targets of immune cells for cancer immunotherapy.](thnov10p0281g004){#F4}

![Potential microRNA targets of immune cells for cancer immunotherapy. The microRNAs either contribute to or repress the immune cells to initiate anti-tumor responses.](thnov10p0281g005){#F5}

![Schematic illustration of antigen cross-presentation by mRNA-based nanovaccine in APC.](thnov10p0281g006){#F6}

![Schematic representation of mRNA nanotherapeutics for T cell engineering. The nanocarriers delivery CAR mRNA to T cells, and induce T cells activation by expressing the CAR protein on the surface of T cells.](thnov10p0281g007){#F7}

![A. The mechanism of CRISPR-Cas9 technology for gene editing. B. CRISPR-Cas 9 nanotherapeutics for cell engineering and the applications in cancer immunotherapy. The CRISPR-Cas 9 system (sgRNA with Cas9 mRNA or DNA or protein) was transported to tumor or immune cells by nanocarriers.](thnov10p0281g008){#F8}

###### 

Nanoparticle-based platforms for RNA delivery

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nanocarriers                  Classifications                                                                              Advantages                                                                                                                                                     Disadvantages
  ----------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Lipid-based nanostructures    Liposomes; solid lipid nanoparticles; lipid emulsions                                        Easy preparation, good biocompatibility and biodegradability                                                                                                   Limited stability, easy leakage of payloads, and rapid clearance

  Polymer-based nanomaterials   Natural or naturally derived polymers: chitosan, poly-l-lysine, atelocollagen, etc.\         Good biocompatibility and biodegradability for natural or naturally derived polymers, low cost of production, stimulation of drug release, easy modification   Nondegradable for some responsive polymers, dose-dependent toxicity
                                Synthetic polymers: PLGA, PEI, PVA, PLA, PEG, etc.                                                                                                                                                                                                          

  Inorganic NPs                 MSNs, CNTs, QDs, and metal nanoparticles (e.g., iron oxide and gold nanoparticles)           Easy surface modification, good reproducibility, and easy cell uptake                                                                                          Non-biodegradability, potential toxicity

  Bio-inspired nano-vehicles    DNA-based nanostructures, exosome-mimetic nanovesicles, red blood cell member-based ghosts   Good biodegradability, low toxicity, strong targeting and low immune induction                                                                                 High cost, stability concern
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of siRNA-based nanotherapeutics for tumor immunotherapy

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cells                                                 Nanocarriers                           Targeted gene                                                                                     Immunological effects                                                          Ref.
  ----------------------------------------------------- -------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------
  Tumor cells                                           PCL-PEG/PCL-PEI                        PD-L1                                                                                             Checkpoint blockade                                                            [@B78]

  FA-PEI polymers                                       PD-L1                                  Checkpoint blockade                                                                               [@B79]                                                                         

  Acidity-Responsive Micelleplex                        PD-L1                                  Checkpoint blockade                                                                               [@B80]                                                                         

  Acid-activatable micelleplex (PDPA based)             PD-L1                                  Checkpoint blockade                                                                               [@B81]                                                                         

  Au-CGKRK nanoconjugates                               PD-L1, STAT3                           Anti-proliferation and checkpoint blockade                                                        [@B82]                                                                         

  Liposome-protamine-hyaluronic acid NPs                TGF-β                                  Decrease TGF-β and enhance the antigen-specific immune response                                   [@B83]                                                                         

  ROS-responsive NPs                                    TGF-β                                  Modify the immunosuppress microenvironment                                                        [@B84]                                                                         

  HA-coated liposome                                    CD47                                   Decrease immune escape of tumor cells                                                             [@B85]                                                                         

  Glutamine-functionalized branched polyethyleneimine   CD47                                   Induce evasion of phagocytic clearance                                                            [@B86]                                                                         

  Chitosan lactate                                      CD-73                                  Attenuate the immunosuppressive microenvironment of the tumor                                     [@B87]                                                                         

  The extracellular vesicles (EVs)                      β-catenin                              Combo therapy with ICB                                                                            [@B88]                                                                         

  T cells                                               Lipid-coated calcium phosphate (LCP)   PD-1                                                                                              Checkpoint blockade                                                            [@B89]

  PEG-PLA                                               CTLA-4                                 Checkpoint blockade                                                                               [@B90]                                                                         

  TAMs                                                  Gold NPs                               TNF-α                                                                                             Silence pro-inflammatory cytokines                                             [@B91]

  Gold NPs                                              VEGF                                   Reduce the recruitment of inflammatory TAMs                                                       [@B92]                                                                         

  Peptides NPs                                          CSF-1R                                 Elimination of M2-like TAMs                                                                       [@B93]                                                                         

  DCs                                                   Gold nanorods or\                      IDO                                                                                               Promote DCs maturation, and increase secretion of pro-inflammatory cytokines   [@B94], [@B95]
                                                        GNRs-PEI                                                                                                                                                                                                                

  Cationic lipid NPs                                    PD-L1,\                                Checkpoint blockade                                                                               [@B96]                                                                         
                                                        PD-L2                                                                                                                                                                                                                   

  PEI based NPs                                         PD-L1                                  Induce immunosuppressive DCs to antigen-presenting cells                                          [@B97]                                                                         

  PEI based NPs                                         IDO                                    Increase secretion of proinflammatory cytokines                                                   [@B98]                                                                         

  PEG-PLL-PLLeu polypeptide micelles                    STAT3                                  Induce DCs maturation and activation, elevate expressions of CD86 and CD40 and IL-12 production   [@B99]                                                                         

  PLGA NPs                                              STAT3                                  Induce DCs maturation and promote antigen cross-presentation                                      [@B100]                                                                        

  Cationic lipid NPs                                    SOCS1                                  Promote production and release of pro-inflammatory cytokines                                      [@B101]                                                                        

  PLGA NPs                                              SOCS1                                  Enhance the production and release of pro-inflammatory cytokines                                  [@B102]                                                                        

  lipid envelope-type NPs                               A20                                    Enhance production of pro-inflammatory molecules after lipopolysaccharide stimulation             [@B103]                                                                        

  Others                                                Lipid/PEG NPs                          CCR2                                                                                              Prevent monocytes accumulation                                                 [@B104]

  PEG/MT/PC NPs                                         VEGF, PIGF                             Anti-proliferation and reverse immune environment                                                 [@B105]                                                                        

  Chitosan NPs                                          Galectin-1                             Reduce polarization to M2 TAMs                                                                    [@B106]                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of microRNA-based nanotherapeutics for cancer immunotherapy

  Cells                          Nanocarriers                    microRNA                 Immunological effects                                                                                                      Ref.
  ------------------------------ ------------------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------- ---------
  T cells                        Exosome-like nanovesicles       miR-150 Antagonist       T-cell regulation                                                                                                          [@B160]
  TAMs                           Layered double hydroxides NPs   miR-155                  Repolarize M2 to M1                                                                                                        [@B161]
  Lipid-coated NPs               miR-155                         Repolarize M2 to M1      [@B158]                                                                                                                    
  CD44 coated HA-PEI based NPs   micR-125b                       Reprogram TAMs into M1   [@B159]                                                                                                                    
  DCs                            Exosomes                        miR-155                  Increase the expressions of MHC-II, CD86, CD40, and CD83, and promote the secretion of the IL12p70, IFN-gamma, and IL-10   [@B162]
                                 PEG-PLL-PLLeu polymeric NPs     miR-148a Antagonist      Reprogram DCs, reduce Treg cells and myeloid-derived suppressor cells                                                      [@B163]
  NK cells                       Exosomes                        miR-186                  Promote NK activation                                                                                                      [@B164]

###### 

Current clinical studies of RNA-mediated immunotherapy for the treatment of cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeting Cell                                                              RNAs Encoding                                                                                  Cancer Types                        Status                     ClinicalTrials.gov Identifier Number
  --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------- -------------------------- --------------------------------------
  T cells                                                                     MET scFv CAR                                                                                   Malignant Melanoma, Breast Cancer   Early Phase 1 Recruiting   NCT03060356

  cMet CAR                                                                    Metastatic Breast Cancer; Triple Negative Breast Cancer                                        Phase 1 Completed                   NCT01837602                

  Chimeric anti-mesothelin immunoreceptor SS1                                 Pancreatic Cancer                                                                              Phase 1 Completed                   NCT01897415                

  DCs                                                                         TAAs: NY-ESO-1, MAGEC1, MAGEC2, 5 T4, Survivin, and MUC1                                       Lung Cancer                         Phase 2 Recruiting         NCT03164772

  TAAs: PSA, PSCA, PSMA, STEAP1, PAP and MUC1                                 Prostate Carcinoma                                                                             Phase 2 Completed                   NCT02140138                

  Neo-Ag                                                                      Melanoma                                                                                       Active\                             NCT02035956                
                                                                                                                                                                             No Recruiting                                                  

  Neo-Ag                                                                      Solid tumor                                                                                    Phase 1 Recruiting                  NCT03313778                

  Neo-Ag                                                                      Melanoma; Colon Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Hepatocellular Cancer   Phase 2 Completed                   NCT03480152                

  Three variant RNAs; p53, and Neo-Ag based on NGS screening                  Breast Cancer (Triple Negative Breast Cancer)                                                  Phase 1 Recruiting                  NCT02316457                

  Carcinoembryonic antigen RNA                                                Colorectal Cancer; Metastatic Cancer                                                           Phase 2 Completed                   NCT00003433                

  Prostate specific antigen (PSA)                                             Prostate Cancer                                                                                Phase 2 Completed                   NCT00004211                

  Carcinoembryonic antigen                                                    Breast Cancer; Colorectal Cancer; Extrahepatic Bile Duct Cancer                                Phase 1 Completed                   NCT00004604                

  Total tumor RNA                                                             Kidney Cancer                                                                                  Phase 1 Completed                   NCT00005816                

  Autologous tumor RNA                                                        Melanoma                                                                                       Phase 3 Recruiting                  NCT01983748                

  TAAs: NYESO-1, MAGE-A3, tyrosinase, and TPTE                                Melanoma                                                                                       Phase 1 Recruiting                  NCT02410733                

  siRNA: LMP2, LMP7, and MECL1; mRNA: MART-1, tyrosinase, gp100, and MAGE-3   Melanoma                                                                                       Phase 1 Completed                   NCT00672542                

  Melan-A, Mage-A1, Mage-A3, Survivin, GP100 and Tyrosinase                   Malignant Melanoma                                                                             Phase 1/2 Completed                 NCT00204516                

  pp65-flLAMP                                                                 Glioblastoma                                                                                   Active No recruiting                NCT03615404                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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